Reference strains of Mycobacteroides abscessus

项目总结 囊性纤维化、支气管扩张和慢性阻塞性肺疾病患者中的非结核 分支杆菌脓肿类杆菌可导致慢性肺部疾病，这种疾病通常是无法治愈的 与快速的肺功能下降有关。此外，现有的治疗需要一年以上的每日治疗。 服用疗效不佳且毒性大的抗生素。脓肿分枝杆菌已被指定为 由于广泛的天然产物，“抗生素噩梦”和“一种环境细菌变成临床噩梦” 和获得性抗生素耐药性，这严重限制了治疗选择。 尽管美国国立卫生研究院最近宣布脓肿分枝杆菌是一种新的感兴趣的病原体，但它是最少的病原体之一。 研究生物体。这项建议的总体目标是鉴定两种临床分离的脓肿分枝杆菌 最近由囊性纤维化、支气管扩张或慢性阻塞性肺疾病患者和 代表了在本上下文中相关的菌株，因此它们可以用作参考菌株 在研究方面。目前用作默认参考菌株的历史脓肿分枝杆菌菌株为 1953年因膝部脓肿被隔离。因此，尚不清楚使用这一遗嘱获得的数据有多大的相关性 对肺部感染和对当今流行菌株的药物敏感性。我们的中心假设是 参考菌株(S)应代表当前临床分离株。我们假设相关的参考菌株是 对于严格的研究是必要的，以便获得的数据将更适用于脓肿分枝杆菌感染 囊性纤维化、支气管扩张症和慢性阻塞性肺疾病患者。

PROJECT SUMMARY In cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease patients, non-tuberculous bacterium Mycobacteroides abscessus can cause chronic pulmonary disease that is often incurable and associated with rapid lung function decline. Additionally, existing treatment requires more than a year of daily intake of antibiotics with poor efficacies and significant toxicities. M. abscessus has been designated as an “antibiotic nightmare” and “an environmental bacterium turned clinical nightmare” due to extensive natural and acquired antibiotic resistance, which severely limits treatment options. Although the NIH recently declared M. abscessus as an emerging pathogen of interest, it is one of the least studied organisms. The overall aim of this proposal is to identify two clinical M. abscessus isolates that were recently derived from cystic fibrosis, bronchiectasis or chronic obstructive pulmonary disease patients and are representative of the strains relevant in the present context so that they can be used as reference strains in research. The historical M. abscessus strain that is currently used as the default reference strain was isolated in 1953 from a knee abscess. Therefore, it is unknown how relevant the data obtained using this will be to pulmonary infections and drug susceptibilities to strains prevalent today. Our central hypothesis is that reference strain(s) should represent current clinical isolates. We postulate a relevant reference strain is necessary for rigorous research so that the data obtained will be more applicable to M. abscessus infections in cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease patients.